Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development

European Journal of Cancer

Volumn 42, Issue 16, 2006, Pages 2821-2832

  Kruczynski, Anna ^a   Poli, Maura ^b   Dossi, Romina ^b   Chazottes, Eric ^a   Berrichon, Géraldine ^a   Ricome, Christel ^a   Giavazzi, Raffaella ^b   Hill, Bridget T ^a   Taraboletti, Giulia ^b  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Angiogenesis inhibition; Experimental metastases; Low subtherapeutic doses; Vascular disrupting effects

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CISPLATIN; VINCA ALKALOID; VINFLUNINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG SPECIFICITY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LOW DRUG DOSE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; FEMALE; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; MICROTUBULES; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED; VINBLASTINE; VINCA ALKALOIDS;

EID: 33750075041     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.06.019     Document Type: Article

References (34)

1. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175 (1972) 409-416
2. Taraboletti G., and Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol 1 (2001) 378-384
3. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nature Reviews 2 (2002) 727-739
4. Ferrara N., and Kerbel R.S. Antiangiogenesis as a therapeutic target. Nature 438 (2005) 967-974
5. Brown J.M., and Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58 (1998) 1408-1416
6. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nature Rev 5 (2005) 423-435
7. Neri D., and Bicknell R. Tumour vascular targeting. Nature Rev 5 (2005) 436-446
8. Belotti D., Vergani V., Drudis T., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2 (1996) 1843-1849
9. Chaplin D.J., Pettit G.R., Parkins C.S., et al. Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents. Br J Cancer 74 (1996) S86-S88
10. Klauber N., Parangi S., Flynn E., et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57 (1997) 81-86
11. Micheletti G., Poli M., Borsotti P., et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63 (2003) 1534-1537
12. Vacca A., Lurlalo M., Ribatti D., et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94 (1999) 4143-4155
13. Geffen D.B., and Man S. New drugs for the treatment of cancer. Isr Med Assoc J 4 (2002) 1124-1131
14. Jassem J., Kosmidis P., Ramlau R., et al. Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann Oncol 14 (2003) 1634-1639
15. Lewis R., Bagnall A.M., King S., et al. The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation. Health Technol Assess 6 (2002) 1-269
16. Walczak J.R., and Carducci M.A. Pharmacological treatments for prostate cancer. Expert Opin Invest Drugs 11 (2002) 1737-1748
17. Fahy J., Duflos A., Ribet J.-P., et al. Vinca alkaloids in superacid media: a method for creating a new family of antitumor derivatives. J Am Chem Soc 119 (1997) 8576-8577
18. Kruczynski A., and Hill B.T. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol/Hematol 40 (2001) 159-173
19. Ngan V.K., Bellman K., Panda D., et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 60 (2000) 5045-5051
20. Lobert S., Ingram J.W., Hill B.T., et al. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 53 (1998) 908-915
21. Holwell S.E., Hill B.T., and Bibby M.C. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer 84 (2001) 290-295
22. Taraboletti G., Micheletti G., Rieppi M., et al. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res 8 (2002) 1182-1188
23. Kruczynski A., Colpaert F., Tarayre J.-P., et al. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 41 (1998) 437-447
24. Passaniti A., Taylor R.M., Pili R., et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 67 (1992) 519-528
25. Hill B.T., Fiebig H.H., Waud W.R., et al. Superior in vivo experimental antitumor activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 35 (1999) 512-520
26. Langdon S.P., Hendriks H.R., Pratesi G., et al. Preclinical phase II studies in human tumour xenografts: a European European multicenter follow-up study. Ann Oncol 5 (1994) 415-422
27. Jordan M.A., and Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10 (1998) 123-130
28. Pasquier E., Honore S., Pourroy B., Jordan M.A., Lehman M., Briand C., et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 65 (2005) 2433-2440
29. Chaplin D.J., and Dougherty G.J. Tumor vasculature as a target for cancer therapy. Br J Cancer 80 (1999) 57-64
30. Kruczynski A., Barret J.M., Etiévant C., Colpaert F., Fahy J., and Hill B.T. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 55 (1998) 635-648
31. Tozer G.M., Prise V.E., Wilson J., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59 (1999) 1626-1634
32. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105 (2000) R15-R24
33. Kerbel R.S., and Kamen B. The anti-angiogenic basis of metronomic chemotherapy. Nature Rev 4 (2004) 423-436
34. Munoz R., Shaked Y., Bertolini F., Emmenegger U., Man S., and Kerbel R.S. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. The Breast 14 (2005) 466-479